Jennifer L Good sold $35k of TRVI
President & CEO at Trevi Therapeutics, Inc.. 5,263 shares at an average of $6.58, traded Mar 21, 2025, filed Mar 25, 2025.
Score components
- +25RoleCEO
- +6Trade size$35k at market
- 0Share of holdings soldSold 2.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-044436, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 21, 2025 | MOption exercise Common Stock | +5,263 | $1.43 | $7,526 | 218,576 | Mar 25, 2025 |
| Mar 21, 2025 | SOpen-market sale Common Stock | -5,263 | $6.58 | $35k | 213,313 | Mar 25, 2025 |
| Mar 21, 2025 | MOption exercise Stock Option (right to buy)derivative | -5,263 | $0.00 | $0 | 0 | Mar 25, 2025 |
Related signals
Other insiders at Trevi Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Trevi Therapeutics, Inc. | Michael Thomas Heffernan director | $596k 39,473 shares | -159% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.